Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13900816 | 0.81 | PTGS2 (0.54) | DHFRPTGS2LMNAHPGDTP53 | |
| SCHEMBL18476024 | 0.79 | MAPT (0.47) | DHFRPTGS2LMNAHPGDTP53 | |
| SCHEMBL9158374 | 0.79 | DHFR (0.49) | DHFRPTGS2LMNAHPGDTP53 | |
| SCHEMBL7968048 | 0.79 | ALDH1A1 (0.43) | LMNAHPGDTP53CYP3A4ALOX15 | |
| SCHEMBL29548140 | 0.78 | DHFR (0.43) | DHFRPTGS2TP53PTGS1ALDH1A1 | |
| SCHEMBL4730685 | 0.76 | DHFR (0.43) | DHFRPTGS2LMNAHPGDTP53 | |
| SCHEMBL6567279 | 0.76 | DHFR (0.43) | DHFRPTGS2LMNAHPGDTP53 | |
| SCHEMBL1304740 | 0.76 | PTGS2 (0.50) | DHFRPTGS2LMNAHPGDTP53 | |
| SCHEMBL8812831 | 0.75 | NR1H4 (0.46) | LMNAHPGDTP53CYP3A4ALOX15 | |
| SCHEMBL29548450 | 0.75 | DHFR (0.49) | DHFRPTGS2LMNAHPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170038642-A1 | ALIGNMENT LAYER AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-09 | — | — | US | disclosed |
| US-20170038642-A1 | ALIGNMENT LAYER AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-09 | — | — | US | disclosed |
| US-20160185763-A1 | LIQUID CRYSTAL STABILIZER, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185763-A1 | LIQUID CRYSTAL STABILIZER, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| EP-0848004-B1 | PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-5955616-A | PROSTAGLANDIN INHIBITORS | SHIONOGI & CO., LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| EP-0848004-A1 | PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 1998-06-17 | — | — | EP | disclosed |
| US-5747517-A | ALZHEIMER'S DISEASE; PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0677517-A1 | Treatment of Alzheimer's disease employing inhibitors of cathepsin D | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185763-A1 | LIQUID CRYSTAL STABILIZER, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | PYM1, YBX3, MLX | DHFR 4220/4885PTGS2 4147/4885LMNA 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.